2013年9月30日,Relypsa將在Nasdaq IPO,募集1.265億美元

Relypsa Inc. on Friday filed for an initial public offering of up to $126.5 million in common stock as the pharmaceutical company looks to bolster its leading product candidate.

Relypsa said it expects to use the proceeds of the offering for developing and manufacturing costs, among other items, related to its drug patiromer.

Patiromer is intended for the treatment of hyperkalemia, a potentially fatal condition characterized by elevated levels of potassium in the blood. It occurs most frequently in people with chronic kidney disease, according to the company.

Subjects have just finished a two-part Phase 3 trial of patiromer, Relypsa said. The first part of the trial met its primary and secondary efficacy endpoints, the company said, adding that it expects to report results of the second part in the fourth quarter this year. It also expects to submit a new drug application to the Food and Drug Administration in the third quarter of next year.

For the six months ended June 30, Relypsa reported a wider loss compared with the year-ago period as research and development expenses nearly doubled.

The company said it applied to be listed on the Nasdaq Global Market, but it didn't specify a ticker symbol.